Methylation of SFRP5 is related to multidrug resistance in leukemia cells

Cancer Gene Therapy

Volumn 21, Issue 2, 2014, Pages 83-89

  Wang, H ^a   Wang, X ^a   Hu, R ^a   Yang, W ^a   Liao, A ^a   Zhao, C ^a   Zhang, J ^a   Liu, Z ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

catenin; mdr1; methylation of SFRP; multidrug resistance; P glycoprotein; Wnt

Indexed keywords

ANALYSIS OF VARIANCE; BETA CATENIN; BLOTTING, WESTERN; CELL LINE, TUMOR; DNA METHYLATION; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; EYE PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITORY CONCENTRATION 50; LEUKEMIA; MEMBRANE PROTEINS; P-GLYCOPROTEIN; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TETRAZOLIUM SALTS; THIAZOLES; WNT SIGNALING PATHWAY;

EID: 84894278517     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2013.87     Document Type: Article

References (41)

1. Finch PW, He X, Kelley MJ, Uren A, Schaudies RP, Popescu NC et al. Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action. Proc Natl Acad Sci USA 1997; 94: 6770-6775.
2. Kinoshita T, Nomoto S, Kodera Y, Koike M, Fujiwara M, Nakao A. Decreased expression and aberrant hypermethylation of the SFRP genes in human gastric cancer. Hepatogastroenterology 2011; 58: 1051-1056.
3. Liu JB, Qiang FL, Dong J, Cai J, Zhou SH, Shi MX et al. Plasma DNA methylation of Wnt antagonists predicts recurrence of esophageal squamous cell carcinoma. World J Gastroenterol 2011; 17: 4917-4921.
4. Kawakami K, Yamamura S, Hirata H, Ueno K, Saini S, Majid S et al. Secreted frizzled-related protein-5 is epigenetically downregulated and functions as a tumor suppressor in kidney cancer. Int J Cancer 2011; 128: 541-550.
5. Lin YW, Chung MT, Lai HC, De Yan M, Shih YL, Chang CC et al. Methylation analysis of SFRP genes family in cervical adenocarcinoma. J Cancer Res Clin Oncol 2009; 135: 1665-1674.
6. Weisberg E, Sattler M, Ray A, Griffin JD. Drug resistance in mutant FLT3-positive AML. Oncogene 2010; 29: 5120-5134.
7. Baguley BC. Multiple drug resistance mechanisms in cancer. Mol Biotechnol 2010; 46: 308-316.
8. Li Y, Yuan H, Yang K, Xu W, Tang W, Li X. The structure and functions of P-glycoprotein. Curr Med Chem 2010; 17: 786-800.
9. Kikuchi A, Yamamoto H, Sato A, Matsumoto S. New insights into the mechanism of Wnt signaling pathway activation. Int Rev Cell Mol Biol 2011; 291: 21-71.
10. Amado NG, Fonseca BF, Cerqueira DM, Neto VM, Abreu JG. Flavonoids: potential Wnt/beta-catenin signaling modulators in cancer. Life Sci 2011; 89: 545-554.
11. Lim JC, Kania KD, Wijesuriya H, Chawla S, Sethi JK, Pulaski L et al. Activation of beta-catenin signaling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem 2008; 106: 1855-1865.
12. Jost E, Schmid J, Wilop S, Schubert C, Suzuki H, Herman JG et al. Epigenetic inactivation of secreted Frizzled-related proteins in acute myeloid leukemia. Br J Haematol 2008; 142: 745-753.
13. Roman-Gomez J, Cordeu L, Agirre X, Jimenez-Velasco A, San Jose-Eneriz E, Garate L et al. Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. Blood 2007; 109: 3462-3469.
14. Liu TH, Raval A, Chen SS, Matkovic JJ, Byrd JC, Plass C. CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia. Cancer Res 2006; 66: 653-658.
15. Griffiths EA, Gore SD, Hooker C, McDevitt MA, Karp JE, Smith BD et al. Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation. Leuk Lymphoma 2010; 51: 1711-1719.
16. Li Y, Rankin SA, Sinner D, Kenny AP, Krieg PA, Zorn AM. Sfrp5 coordinates foregut specification and morphogenesis by antagonizing both canonical and noncanonical Wnt11 signaling. Genes Dev 2008; 22: 3050-3063.
17. Su HY, Lai HC, Lin YW, Liu CY, Chen CK, Chou YC et al. Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int J Cancer 2010; 127: 555-567.
18. Ho CM, Lai HC, Huang SH, Chien TY, Lin MC, Chang SF. Promoter methylation of sFRP5 in patients with ovarian clear cell adenocarcinoma. Eur J Clin Invest 2010; 40: 310-318.
19. Veeck J, Geisler C, Noetzel E, Alkaya S, Hartmann A, Knuchel R et al. Epigenetic inactivation of the secreted frizzled-related protein-5 (SFRP5) gene in human breast cancer is associated with unfavorable prognosis. Carcinogenesis 2008; 29: 991-998.
20. Filipovich A, Gehrke I, Poll-Wolbeck SJ, Kreuzer KA. Physiological inhibitors of Wnt signaling. Eur J Haematol 2011; 86: 453-465.
21. Yao H, Ashihara E, Maekawa T. Targeting the Wnt/beta-catenin signaling pathway in human cancers. Expert Opin Ther Targets 2011; 15: 873-887.
22. Verkaar F, Zaman GJ. New avenues to target Wnt/beta-catenin signaling. Drug Discov Today 2011; 16: 35-41.
23. Gandhirajan RK, Poll-Wolbeck SJ, Gehrke I, Kreuzer KA. Wnt/beta-catenin/LEF-1 signaling in chronic lymphocytic leukemia (CLL): a target for current and potential therapeutic options. Curr Cancer Drug Targets 2010; 10: 716-727.
24. Prosperi JR, Goss KH. A Wnt-ow of opportunity: targeting the Wnt/beta-catenin pathway in breast cancer. Curr Drug Targets 2010; 11: 1074-1088.
25. Wang Y, van der Zee M, Fodde R, Blok LJ. Wnt/Beta-catenin and sex hormone signaling in endometrial homeostasis and cancer. Oncotarget 2010; 1: 674-684.
26. De A. Wnt/Ca2\+ signaling pathway: a brief overview. Acta Biochim Biophys Sin (Shanghai) 2011; 43: 745-756.
27. Wansleeben C, Meijlink F. The planar cell polarity pathway in vertebrate development. Dev Dyn 2011; 240: 616-626.
28. Montcouquiol M, Crenshaw 3rd EB, Kelley MW. Noncanonical Wnt signaling and neural polarity. Annu Rev Neurosci 2006; 29: 363-386.
29. Dabdoub A, Kelley MW. Planar cell polarity and a potential role for a Wnt morphogen gradient in stereociliary bundle orientation in the mammalian inner ear. J Neurobiol 2005; 64: 446-457.
30. El Wakil A, Lalli E. The Wnt/beta-catenin pathway in adrenocortical development and cancer. Mol Cell Endocrinol 2011; 332: 32-37.
31. Ravna AW, Sager G. Molecular modeling studies of ABC transporters involved in multidrug resistance. Mini Rev Med Chem 2009; 9: 186-193.
32. Knez L, Sodja E, Kern I, Kosnik M, Cufer T. Predictive value of multidrug resistance proteins, topoisomerases II and ERCC1 in small cell lung cancer: a systematic review. Lung Cancer 2011; 72: 271-279.
33. Shekhar MP. Drug resistance: challenges to effective therapy. Curr Cancer Drug Targets 2011; 11: 613-623.
34. Chen ZS, Tiwari AK. Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. FEBS J 2011; 278: 3226-3245.
35. Slot AJ, Molinski SV, Cole SP. Mammalian multidrug-resistance proteins (MRPs). Essays Biochem 2011; 50: 179-207.
36. Koenderink JB, Kavishe RA, Rijpma SR, Russel FG. The ABCs of multidrug resistance in malaria. Trends Parasitol 2010; 26: 440-446.
37. Tamaki A, Ierano C, Szakacs G, Robey RW, Bates SE. The controversial role of ABC transporters in clinical oncology. Essays Biochem 2011; 50: 209-232.
38. Pan GD, Yang JQ, Yan LN, Chu GP, Liu Q, Xiao Y et al. Reversal of multi-drug resistance by pSUPER-shRNA-mdr1 in vivo and in vitro. World J Gastroenterol 2009; 15: 431-440.
39. Ye X, Liu T, Gong Y, Zheng B, Meng W, Leng Y et al. interference reversing the drug-resistance in MDR1 single-factor resistant cell line K562/MDR1. Leuk Res 2009; 33: 1114-1119.
40. Ren Y, Wang Y, Zhang Y, Wei D.. Overcoming multidrug resistance in human carcinoma cells by an antisense oligodeoxynucleotide-doxorubicin conjugate in vitro and in vivo. Mol Pharm 2008; 5: 579-587.
41. Leslie EM, Deeley RG, Cole SP.. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005; 204: 216-237.